Last reviewed · How we verify
NCT04515108
Perinatal Outcomes and Hematologic Parameters in COVID-19 Pregnancies
trial testing Clinical assessment in Pregnancy, Infections in in 108 participants. Completed in 10 August 2020.
5 August 2020
Quick facts
| Lead sponsor | Ankara City Hospital Bilkent |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 108 |
| Start date | 10 March 2020 |
| Primary completion | 5 August 2020 |
| Estimated completion | 10 August 2020 |
| Sites | 1 location across Turkey (Türkiye) |
Drugs / interventions tested
- Clinical assessment — full drug profile →
Conditions studied
- Pregnancy, Infections in — all drugs for Pregnancy, Infections in →
- Covid19 — all drugs for Covid19 →
Sponsor
Ankara City Hospital Bilkent
Who can join
Adults 18 to 42, female only, with Pregnancy, Infections in or Covid19. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Complete blood count parameters are routinely evaluated cost-effective markers in diagnosis and clinical follow-up of infectious diseases.There is increasing number of studies to report the course of COVID-19 in pregnancy. The current study aimed to elucidate the changes in hematologic parameters in response to SARS-CoV-2 infection and whether there was an increase in adverse perinatal outcomes such as increased neonatal intensive care unit admission and lower APGAR scores in pregnancies with COVID-19.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04515108
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Clinical assessment
Trials testing the same drug.
- NCT06997380 — Evaluation of the Safety and Efficacy of an Injectable Liposomal Gel · NA · enrolling by invitation
- NCT06411028 — Factors Determining the Efficacy of Botulinum Toxin for Arm Tremor in Dystonia · Phase 4 · recruiting
- NCT06008704 — Pain in Parkinson's Disease: Exploration of the Serotonin System in Positron Emission Tomography (PET [18F]-MPPF) · NA · recruiting
- NCT05932589 — Neurophysiologic Biomarkers in Rett Syndrome · recruiting
- NCT06014697 — OCT and Invasion in Cutaneous Skin Lesions · completed
Other Ankara City Hospital Bilkent trials
Trials by the same sponsor.
- NCT07496788 — Investigation of the Role of Internal Jugular Vein Collapsibility Index in Predicting Spinal Anesthesia-Induced Hypotens · not yet recruiting
- NCT07536464 — PEEP Strategies and Mechanical Power in Robotic Surgery · NA · not yet recruiting
- NCT07534553 — Mechanical Power Ventilation in RALP · NA · not yet recruiting
- NCT07501468 — Ventilation Safety in Beach Chair Shoulder Surgery: SafeLM Versus I-gel · NA · not yet recruiting
- NCT07502209 — Suprascapular Nerve PRF in Chronic Shoulder Pain · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04515108 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Ankara City Hospital Bilkent
- Last refreshed: 17 August 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04515108.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing